Volume 63, Issue 1

The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach

Z. Yuan

Corresponding Author

Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, U.S.A.

email:zyuan1@prdus.jnj.comSearch for more papers by this author
R. Chappell

Department of Statistics, University of Wisconsin‐Madison, Madison, Wisconsin 53706, U.S.A.

Search for more papers by this author
H. Bailey

Department of Medicine, University of Wisconsin‐Madison, Madison, Wisconsin 53792, U.S.A.

Search for more papers by this author
First published: 16 April 2007
Citations: 67

Abstract

Summary We consider the case of phase I trials for treatment of cancer or other severe diseases in which grade information is available about the severity of toxicity. Most dose allocation procedures dichotomize toxicity grades based on being dose limiting, which may not work well for severe and possibly irreversible toxicities such as renal, liver, and neurological toxicities, or toxicities with long duration. We propose a simple extension to the continual reassessment method (CRM), called the Quasi‐CRM, to incorporate grade information. Toxicity grades are first converted to numeric scores that reflect their impacts on the dose allocation procedure, and then incorporated into the CRM using the quasi‐Bernoulli likelihood. A simulation study demonstrates that the Quasi‐CRM is superior to the standard CRM and comparable to a univariate version of the Bekele and Thall method (2004, Journal of the American Statistical Association99, 26–35). We also present sensitivity analysis of the new method with respect to toxicity scores, and discuss practical issues such as extending the simple algorithmic up‐and‐down designs.

Number of times cited according to CrossRef: 67

  • A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades, Stats, 10.3390/stats3030017, 3, 3, (221-238), (2020).
  • Model-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_3, (33-79), (2019).
  • A dose finding design for seizure reduction in neonates, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12289, 68, 2, (427-444), (2018).
  • gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12263, 68, 2, (289-308), (2018).
  • Modeling adverse event counts in phase I clinical trials of a cytotoxic agent, Clinical Trials, 10.1177/1740774518772309, 15, 4, (386-397), (2018).
  • The Evolution of Phase I Trials, Past, Present, and Future, Novel Designs of Early Phase Trials for Cancer Therapeutics, 10.1016/B978-0-12-812512-0.00003-8, (17-32), (2018).
  • Changing Landscape of Early Phase Clinical Trials, Novel Designs of Early Phase Trials for Cancer Therapeutics, 10.1016/B978-0-12-812512-0.00001-4, (1-6), (2018).
  • Bayesian optimal interval design with multiple toxicity constraints, Biometrics, 10.1111/biom.12912, 74, 4, (1320-1330), (2018).
  • A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies, BMC Medical Research Methodology, 10.1186/s12874-018-0604-9, 18, 1, (2018).
  • An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1462727, 10, 3, (185-195), (2018).
  • Dose-finding designs for cumulative toxicities using multiple constraints, Biostatistics, 10.1093/biostatistics/kxx059, 20, 1, (17-29), (2017).
  • Dose-finding designs for trials of molecularly targeted agents and immunotherapies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1289952, 27, 3, (477-494), (2017).
  • Ranking ultimate teams using a Bayesian score-augmented win-loss model, Journal of Quantitative Analysis in Sports, 10.1515/jqas-2016-0097, 13, 2, (2017).
  • Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile, PLOS ONE, 10.1371/journal.pone.0170187, 12, 1, (e0170187), (2017).
  • Nonparametric overdose control with late-onset toxicity in phase I clinical trials, Biostatistics, 10.1093/biostatistics/kxw038, 18, 1, (180-194), (2016).
  • Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials, Advanced Statistical Methods in Data Science, 10.1007/978-981-10-2594-5_4, (55-74), (2016).
  • A Review of Dose Finding Methods and Theory, Communications for Statistical Applications and Methods, 10.5351/CSAM.2015.22.5.401, 22, 5, (401-413), (2015).
  • On the consistency of the continual reassessment method with multiple toxicity constraints, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2015.03.001, 164, (1-9), (2015).
  • Phase 1 adaptive dose‐finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high‐risk extremity and trunk soft tissue sarcoma, Cancer, 10.1002/cncr.29544, 121, 20, (3659-3667), (2015).
  • Phase I trial design for drug combinations with Bayesian model averaging, Pharmaceutical Statistics, 10.1002/pst.1668, 14, 2, (108-119), (2015).
  • Dose finding with longitudinal data: simpler models, richer outcomes, Statistics in Medicine, 10.1002/sim.6552, 34, 22, (2983-2998), (2015).
  • The Changing Landscape of Phase I Trials in Oncology, American Society of Clinical Oncology Educational Book, 10.14694/EdBook_AM.2015.35.3, 35, (3-8), (2015).
  • The changing landscape of phase I trials in oncology, Nature Reviews Clinical Oncology, 10.1038/nrclinonc.2015.194, 13, 2, (106-117), (2015).
  • Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920873, 25, 5, (903-920), (2014).
  • A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774514555585, 12, 1, (24-33), (2014).
  • Dose finding with continuous outcome in phase I oncology trials, Pharmaceutical Statistics, 10.1002/pst.1662, 14, 2, (102-107), (2014).
  • Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2014.02.004, 37, 2, (322-332), (2014).
  • Phase I Trials including Phase I Cancer Trials, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
  • Phase I Trials, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (682-691), (2014).
  • Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control, Statistics in Medicine, 10.1002/sim.6201, 33, 22, (3815-3829), (2014).
  • Simple benchmark for complex dose finding studies, Biometrics, 10.1111/biom.12158, 70, 2, (389-397), (2014).
  • The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach, PLoS ONE, 10.1371/journal.pone.0098147, 9, 5, (e98147), (2014).
  • Incorporating adverse event relatedness into dose‐finding clinical trial designs, Statistics in Medicine, 10.1002/sim.6011, 33, 7, (1146-1161), (2013).
  • Advances in Statistical Approaches to Oncology Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479013501309, 48, 1, (81-89), (2013).
  • Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials, The Open Medical Informatics Journal, 10.2174/1874431101307010008, 7, 1, (8-17), (2013).
  • A pragmatic dose‐finding approach using short‐term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials, Pharmaceutical Statistics, 10.1002/pst.1590, 12, 5, (315-327), (2013).
  • Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities, Statistics in Medicine, 10.1002/sim.5737, 32, 16, (2728-2746), (2013).
  • Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2013.789892, 23, 4, (856-870), (2013).
  • Adaptive designs for dual-agent phase I dose-escalation studies, Nature Reviews Clinical Oncology, 10.1038/nrclinonc.2013.35, 10, 5, (277-288), (2013).
  • Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials, Journal of Probability and Statistics, 10.1155/2012/317634, 2012, (1-18), (2012).
  • Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774512443593, 9, 3, (303-313), (2012).
  • The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs., Japanese Journal of Biometrics, 10.5691/jjb.33.31, 33, 1, (31-76), (2012).
  • Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2012.04.007, 33, 5, (949-958), (2012).
  • Designs for Phase I Trials, Designs for Clinical Trials, 10.1007/978-1-4614-0140-7, (1-27), (2012).
  • References, Clinical Trial Design, undefined, (311-327), (2012).
  • Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2012.676586, 22, 4, (785-801), (2012).
  • Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511411593, 10, 3, (414-421), (2011).
  • Toxicity burden score: a novel approach to summarize multiple toxic effects, Annals of Oncology, 10.1093/annonc/mdr146, 23, 2, (537-541), (2011).
  • Incorporating lower grade toxicity information into dose finding designs, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511410732, 8, 4, (370-379), (2011).
  • Bayesian Methods and Applications, Modern Issues and Methods in Biostatistics, 10.1007/978-1-4419-9842-2_10, (261-289), (2011).
  • Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading, Statistics in Medicine, 10.1002/sim.4069, 30, 17, (2070-2080), (2011).
  • Continual reassessment method with multiple toxicity constraints, Biostatistics, 10.1093/biostatistics/kxq062, 12, 2, (386-398), (2010).
  • A modified toxicity probability interval method for dose-finding trials, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774510382799, 7, 6, (653-663), (2010).
  • Bayesian Approach for Adaptive Design, Handbook of Adaptive Designs in Pharmaceutical and Clinical Development, 10.1201/b10279, (3-1-3-19), (2010).
  • A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2010.05.010, 31, 5, (473-482), (2010).
  • Advances in Oncology Clinical Research: Statistical and Study Design Methodologies, Lung Cancer, 10.1007/978-1-60761-524-8, (467-481), (2010).
  • Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score, Biometrics, 10.1111/j.1541-0420.2009.01297.x, 66, 2, (541-548), (2009).
  • Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials, Biometrics, 10.1111/j.1541-0420.2009.01302.x, 66, 2, (532-540), (2009).
  • Sensitivity of dose-finding studies to observation errors, Contemporary Clinical Trials, 10.1016/j.cct.2009.06.008, 30, 6, (523-530), (2009).
  • Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials, Journal of the American Statistical Association, 10.1198/jasa.2009.ap08425, 104, 487, (954-968), (2009).
  • Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations, Statistics in Biopharmaceutical Research, 10.1198/sbr.2009.0014, 1, 3, (213-228), (2009).
  • An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations, Journal of Biopharmaceutical Statistics, 10.1080/10543400802609805, 19, 2, (247-255), (2009).
  • Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach, Biometrics, 10.1111/j.1541-0420.2008.01045.x, 65, 1, (307-315), (2008).
  • A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents, Biometrics, 10.1111/j.1541-0420.2008.01119.x, 65, 3, (866-875), (2008).
  • A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2007.12.008, 90, 3, (240-250), (2008).
  • Sequential continual reassessment method for two‐dimensional dose finding, Statistics in Medicine, 10.1002/sim.3372, 27, 27, (5664-5678), (2008).
  • Phase I Trials, Wiley Encyclopedia of Clinical Trials, 10.1002/9780471462422, (1-8), (2007).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.